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Abstract
In this article the co-existence of pulmonary emphysema with lung fibrosis of typical pattern and distribution for usual interstitial 
pneumonia (UIP) was compared with idiopathic pulmonary fibrosis (IPF) alone. Author discusses the etiopathogenesis of these 
diseases, differences in signaling pathways and the role of senescent cells. Moreover, clinical course, pulmonary function tests 
as well as main complications are reviewed. However, the lack of well-established diagnostic criteria for CPFE along with mainly 
retrospective character of the studies make current knowledge about this entity rather deficient.
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Introduction
At the first glimpse the two entities are very 
similar. Idiopathic pulmonary fibrosis (IPF) is 
a progressive disease with fibrosis of the lung 
alveoli and interstitium of unknown etiology, 
but poor prognosis (median survival 3–4 years). 
Combined pulmonary fibrosis and emphysema 
(CPFE) comprises, besides lung fibrosis, pulmo-
nary emphysema with typical distribution. IPF 
as well as CPFE present with UIP (usual inter-
stitial pneumonia) pattern of fibrosis: reticular 
opacities, honeycombing with or without traction 
bronchiectasis, localized in subpleural, bottom 
parts of the lungs in the lower lobes [1]. Besides 
fibrotic changes, cenrtilobular and/or paraseptal 
emphysema or bullous changes in the upper lo-
bes are characteristic of CPFE. Emphysema can 
also be present in IPF patients as reticulation 
admixed emphysema and may mimic honey-
combing [2, 3]. Of note, emphysema concomitant 
with interstitial lung disease is not only specific 
for IPF pattern [4].
CPFE is a quite new entity. In 1990 Wiggins 
et al. [5] for the first time described eight pa-
tients with cryptogenic fibrosing alveolitis with 
emphysema. Fifteen years later, in 2005, Cottin 
et al. [6] gave in clinical, pathophysiological and 
imaging terms — the comprehensive description 
of patients with CPFE. Thus, they proved that 
CPFE is a distinct entity, different from IPF as 
well as from emphysema, with distinct prognosis 
and typical comorbidities (i.e. pulmonary hyper-
tension). Then they have also noticed that the 
disease affected almost exclusively older men, 
heavy smokers. Such a high men predominance 
— 100% in some studies, with the male/female 
ratio 9:1 in the others, while in IPF, this ratio is 
2:1, could not be explained only by the greater 
exposure to cigarette smoke in men [7].
During the last decade, a great progress in 
diagnostic and therapeutic approach to patients 
with IPF has been made. Although the main risk 
factor for lung fibrosis and emphysema is cigarette 
smoke, the pathomechanism of these entities is 
quite different. According to the current view, 
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persistent exposure to the detrimental environ-
mental factors like cigarette smoke, air pollution, 
viral infection in susceptible individuals leads 
to dysregulated cross-talking between epithelial 
and mesenchymal cells [8–10]. Injured alveolar 
epithelial cells orchestrating with recruited in-
flammatory cells, proteinase-antiproteinase im-
balance along with oxidative stress contribute to 
dysregulated epithelial-mesenchymal transition 
(EMT) [8–10]. Released by epithelial and other 
cells pro-fibrotic cytokines, mainly TGF- b, PDGF, 
connective tissue growth factor (CTGF) stimula-
te EMT, activate myofibroblasts, which acquire 
antiapoptotic and invasive properties [11–13]. 
In consequence, the histological hallmark of UIP 
— fibroblastic foci coexist with fibroblasts and 
myofibroblasts. These myofibroblasts with their 
contractile fibrils, mainly a-SMA (alpha smooth 
muscle actin), are presumably responsible for 
alveolar collapse and restrictive phenotype of 
patients with IPF [14].
In the last years, in both IPF and emphysema, 
accelerated senescence associated with decreased 
telomere length was found [15, 16]. About 10% of 
familial IPF patients harbored mutations affecting 
telomerase reverse transcriptase — TERT or telo-
merase RNA component — TERC [17]. According 
to this concept, senescent cells with increased 
b-galactosidase activity as well as P53, P21 and 
P16 proteins acquire antiapoptotic and secretory 
features [18, 19]. Such cells with senescence-as-
sociated secretory phenotype (SASP) produce 
broad repertoire of proinflammatory cytokines, 
chemokines, growth factors influencing neighbo-
ring tissues. Physiologically, the number of sene-
scent cells increases with age [20]. However, in 
IPF, accelerated senescence of epithelial cells and 
fibroblasts with accumulation of these cells in the 
lungs was demonstrated [19, 21]. Furthermore, it 
was revealed that the process is mainly regulated 
by microRNA-34a [22]. Thus, SASP cells emerge 
as the main driver of fibroproliferative mechanism 
perpetuating abnormal epithelial-mesenchymal 
interactions. Moreover, in the murine model, se-
nolytic intervention with disatinib and quercetin 
showed striking improvement in pulmonary and 
physiological functions [21]. If so, this model can 
change the existing paradigm of the fibroblast 
role: from aberrantly activated cells to cells with 
senescence phenotype.
Of note, according to this scenario, in COPD
-emphysema, abnormal senescence is associated 
with mesenchymal cells insufficiency, leading to 
decrease of extracellular matrix and alveolar va-
nishing [23]. On molecular basis, in IPF, Wnt/b — 
catenin and Notch signaling pathways increase, 
which through the complex interactions enhance 
TGF-b concentration [24, 25]. Instead, in COPD
-emphysema these pathways are significantly 
inhibited [23, 26]. So, contrary to IPF, decreased 
ECM components due to increased MMPs activity 
along with depressed fibroblasts function and the-
ir reduced response to TGF-b were reported [27]. 
It is intriguing that in dysregulated inflammatory 
and remodeling processes, similar factors can lead 
to different epithelial-mesenchymal responses, 
favoring either emphysema or fibrosis.
Comparing clinical course of IPF and CPFE, 
many studies indicated much worse prognosis 
of CPFE [7, 28]. Zhang et al. [28] studying the 
Chinese population, found a 5-yr survival rate 
in CPFE subjects at 43% with all-cause mortality 
rate at 56.6%, compared to IPF group with 65.7% 
and 34.4%, respectively. Also composite physio-
logic index (CPI) that represents a combination 
of pulmonary ventilation, diffusing capacity for 
carbon monoxide and chest HRCT score, incre-
ased more dramatically in CPFE patients at each 
point during 36 months of observation. Further-
more, pulmonary hypertension — a  common 
complication in advanced CPFE, was found to 
be an additional predictor of poor prognosis [29].
However, there are also data indicating the 
same [30] or even longer survival in CPFE pa-
tients vs. IPF subjects [31]. In fact, some authors 
reported that median survival of CPFE patients 
with autoimmune markers like ANA, ANCA was 
51 months, compared to 38 months in those with 
negative autoimmune profile (p = 0.052) [32]. 
As might be expected, patients with positive im-
munological markers expressed high level of CD 
20+ cells in lung specimens, forming lymphoid 
follicles adjacent to fibroblast foci. However, these 
observations suggested rather ongoing autoim-
mune disease than CPFE. On the other hand, we 
cannot exclude the possibility that some patients 
with CPFE were included into the IPF group. 
Although the prevalence of CPFE in the general 
population is still unknown — about 8% to 53% of 
those with IPF after reevaluation were identified 
as CPFE patients [33, 34]. That is why the median 
survival in patients with CPFE is reported to cover 
a wide range: from 2.1 to 8.5 years. Moreover, the 
extent of emphysema on CT scans, by different 
researchers is defined as greater than 5%,10%, 
15% or even bigger percentage of the lung volu-
me. Taking into account that too small range of 
emphysema may exert discernible effect on the 
disease, the recently proposed equal to or more 
than 15% — seems to be commonly acceptable.
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As the main risk factor for lung cancer (LC) 
development is cigarette smoke, and emphysema 
is additional independent risk factor [35], one 
might assume that the incidence of LC is higher in 
the CPFE group compared to the IPF one. Kwak et 
al. [36] for the first time analyzing retrospectively 
medical records of patients hospitalized in Seoul 
National University Hospital from 2000 to 2011, 
found similar risk of LC in CPFE patients and IPF 
subjects (HR 1.11, p = 0.845). However, LC risk in 
both groups was significantly higher than that in 
solely emphysema patients (HR 4.62, p = 0.005 
for CPFE and 4.15, p = 0.046 for IPF). Like pre-
viously reported, cancer had mainly subpleural 
localization, in the lower lobes, while in patients 
with emphysema — in the upper lobes [36–38]. 
Furthermore, a 5-year survival rate did not differ 
between the CPFE and IPF group (22% and 22%, 
respectively) [39]. Similar results were reported 
by Sato et al. [40]. However, an extremely low 
5-year survival rate in CPFE subjects comparing 
to the group with sole emphysema (18.7% and 
67.1%, respectively) was also recorded [41]. Of 
note, CPFE patients significantly more frequently 
developed postoperative cardiopulmonary com-
plications than those with IPF (40). Interestingly, 
according to scarce data, squamous cell cancer 
followed by adenocarcinoma were the most com-
mon types in the CPFE group [39, 40]. In the IPF 
group, that sequence may be reversed [39, 40, 42].
As there is no treatment capable of halting or 
reversing these diseases and even no commonly 
accepted therapeutic option is available for those 
with CPFE, the approach to subjects with IPF 
and CPFE is quite the same. Smoking cessation, 
oxygen supplementation, antifibrotic drugs like 
pirfeniden and nintedanib, along with broncho-
dilators in those with obstructive pattern are 
recommended. However, no efficacy of specific 
pulmonary hypertension therapy has been noti-
ced. Like in patients with IPF, lung transplanta-
tion is the last option.
So, what is the role of emphysema  
in CPFE patients?
Due to emphysema, normal or nearly normal 
lung volume is preserved, because hyperinflation 
acts contrarily to fibrosis. However, already dif-
fusing capacity of the lung for carbon monoxide 
is lower than that in IPF subjects. Also higher risk 
for the development of pulmonary hypertension, 
a strong predictor of mortality is observed [29]. 
But no additive impact of emphysema on lung 
cancer development in CPFE patients has been 
found [36]. Interestingly, a few months ago Jacob 
et al. [43], in a  retrospective analysis reported 
that the presence and extent of emphysema had 
no prognostic impact on survival of patients with 
IPF after correction for baseline disease severity. 
Furthermore, only isolated emphysema distant 
from fibrosis was independently associated with 
lower DLCO but had no impact on the lung volu-
me. Whereas emphysema admixed with fibrosis 
exercised no influence on DLCO but preserved 
forced vital capacity.
Looking at the conflicting results of different, 
often retrospective studies based on heterogeneo-
us populations, along with the lack of precise 
CPFE definition as well as treatment consensus 
strategy, it is high time to shed more light on this 
young and still unrecognized disease.
So finally, looking at the data above, it seems 
that IPF and CPFE are rather two different entities.
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